Acitretin systemic and retinoic acid 0.1% cream supression of basal cell carcinoma.
Retinoids have been used for years as monotherapy and/or in combination for treatment and suppression of cutaneous malignancies in patients with basal cell nevus syndrome, xeroderma pigmentosum, or cutaneous T-cell lymphoma (CTCL) basal cell carcinoma (BCC). We report 4 cases with BCC confirmed by histopathology who were treated by short-term systemic acitretin combined with retinoic acid 0.1% cream. The 4 cases with BCC showed good response to the treatment without severe adverse effects during treatment and follow-up. The finding suggests that acitretin may be an appropriate treatment option for elderly patients who require less invasive treatment for BCC.
Guangzhou Institute of Dermatology, Guangzhou, China;
Xi-Bao
XB
Zhang
Guangzhou Institute of Dermatology, Guangzhou, China;
San-Quan
SQ
Zhang
Dongguan Institute of Dermatology, Dongguan, China.
Chang-Xing
CX
Li
Guangzhou Institute of Dermatology, Guangzhou, China;
Zhen-Ming
ZM
Huang
Guangzhou Institute of Dermatology, Guangzhou, China;
Yu-Wu
YW
Luo
acitretin; basal cell carcinoma.